- Conditions
- Pain, Chronic Pain, Hyperalgesia
- Interventions
- Ketamine, Placebos
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1969–1988
of 1,988
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Heart Failure
- Interventions
- Sodium Nitrite Inhalation Solution, Placebo
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Insulin Resistance
- Interventions
- Intralipid, Palm Oil Emulsion, Saline
- Dietary Supplement · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Pediatric Intestinal Failure
- Interventions
- KiteLock 4% Sterile Catheter Lock Solution, Heparin Lock Solution
- Device
- Lead sponsor
- SterileCare Inc.
- Industry
- Eligibility
- 4 Weeks to 18 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- Boston, Massachusetts • Omaha, Nebraska • New York, New York + 5 more
- Conditions
- Muscle Spasticity
- Interventions
- Hyaluronidase, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related
- Interventions
- patisiran (ALN-TTR02), Sterile Normal Saline (0.9% NaCl)
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 13
- States / cities
- La Mesa, California • Orange, California • Denver, Colorado + 9 more
- Conditions
- Pelvic Organ Prolapse
- Interventions
- pudendal block, no pudendal block
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Congestive Heart Failure, Renal Insufficiency
- Interventions
- Hypertonic saline, then oral sodium chloride, Normal saline, then oral placebo capsule
- Drug
- Lead sponsor
- Barnes-Jewish Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Covid19
- Interventions
- Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase), 0.9%sodium chloride
- Drug
- Lead sponsor
- Jon Simmons
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Mobile, Alabama
- Conditions
- Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Interventions
- NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg, Placebo Comparator
- Drug · Other
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 7
- States / cities
- Fairway, Kansas • Worcester, Massachusetts • St Louis, Missouri + 4 more
- Conditions
- COVID-19
- Interventions
- ChAdV68-S, ChAdV68-S-TCE, SAM-LNP-S, SAM-LNP-S-TCE, Sodium Chloride, 0.9%
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Decatur, Georgia • St Louis, Missouri • Houston, Texas + 1 more
- Conditions
- Covid19, Multisystem Inflammatory Syndrome in Children (MIS-C)
- Interventions
- Sulfur hexafluoride lipid-type A microspheres
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Minute to 17 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Primary Sjögren Syndrome
- Interventions
- RSLV-132, Placebo
- Drug
- Lead sponsor
- Resolve Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 24
- States / cities
- Chula Vista, California • Tustin, California • Boca Raton, Florida + 20 more
- Conditions
- Sars-CoV-2 Infection
- Interventions
- Peginterferon lambda alfa-1a subcutaneous injection, Saline
- Drug · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Osteoarthritis
- Interventions
- Ropivacaine, Normal saline, Methylprednisolone
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1273, mRNA-1283, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years to 64 Years
- Enrollment
- 30,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 150
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 127 more
- Conditions
- Orthostatic Hypotension, Falls
- Interventions
- Medication review, Nutrition/Salt intake, Education, Exercise, Drug Recommendations
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 356 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Pneumonia, Hypoxemia, Acute Respiratory Failure, COVID-19 Pneumonia
- Interventions
- Inhaled budesonide and formoterol, Inhaled placebo
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 8 more
- Conditions
- Gastroenteritis Escherichia Coli
- Interventions
- Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
- Other · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Diabetes Mellitus
- Interventions
- Albiglutide 50mg, Albiglutide matching placebo, Exenatide 10microgram, Exenatide placebo (saline)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts